Doxazosin Tablet
Product Images NDC 43063-739

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 43063-739). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063739 Label (43063739)

Label for Doxazosin USP 2 mg tablets by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. Package contains 90 tablets with NDC 43063-739-90. Label includes reorder number 110183, lot number SAMPLE, and expiration date 01/2050. Features a green Rx only warning bar advising to keep out of children's reach and to see package insert for dosage and storage instructions.*

FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Chemical structure diagram of the active ingredient doxazosin, showing its molecular connections and functional groups, consistent with the generic drug doxazosin.*

FDA Label Image

Figure1.jpg (Figure1)

This figure contains two line graphs comparing Doxazosin 2 mg tablets to placebo over 14 weeks. The left graph shows mean change in total symptom score from baseline, with Doxazosin showing greater symptom improvement than placebo. The right graph displays mean increase in maximum urinary flow rate (mL/sec) from baseline, with Doxazosin demonstrating a larger increase compared to placebo. Sample sizes and significance markers are included.*

FDA Label Image

Table3.jpg (Table3)

A data table summarizing effectiveness results from three placebo-controlled studies of Doxazosin. It details symptom score and maximum flow rate changes, including mean baseline values and mean changes for placebo and Doxazosin groups at various doses. The right side includes a bar graph comparing symptom score and maximum flow rate changes in Study 2 across placebo, 4 mg, and 8 mg doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.